Online inquiry

IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2745MR)

This product GTTS-WQ2745MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2745MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5312MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ11734MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ5519MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ10607MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ9396MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ6209MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ9047MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ11058MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW